Drug
Dalzanemdor clinical trials
Also written SAGE-718.
- studies test it
- 11
- open now
- 0
- in phase 3
- 1
- first study started
- 2018
How studies write it
Studies that test it under each name
Development codes
- SAGE-718
- 11
Studies by the year they started
11 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 6
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Studies
Open first, then newest update. How each study uses dalzanemdor is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's DiseaseTerminatedPhase 3Supernus Pharmaceuticals, Inc.NCT05655520Written as SAGE-718
- A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy SubjectsCompletedPhase 1Supernus Pharmaceuticals, Inc.NCT03770780Written as SAGE-718
- A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part BCompletedPhase 1Supernus Pharmaceuticals, Inc.NCT03787758Written as SAGE-718
- A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy SubjectsCompletedPhase 1Supernus Pharmaceuticals, Inc.NCT03771586Written as SAGE-718
- A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy SubjectsCompletedPhase 1Supernus Pharmaceuticals, Inc.NCT03844906Written as SAGE-718
- A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)CompletedPhase 2Supernus Pharmaceuticals, Inc.NCT05619692Written as SAGE-718
- A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)CompletedPhase 2Supernus Pharmaceuticals, Inc.NCT04476017Written as SAGE-718
- A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)CompletedPhase 2Supernus Pharmaceuticals, Inc.NCT04602624Written as SAGE-718
- A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)CompletedPhase 2Supernus Pharmaceuticals, Inc.NCT05107128Written as SAGE-718
- 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's DiseaseCompletedPhase 2Supernus Pharmaceuticals, Inc.NCT05358821Written as SAGE-718
- A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive ImpairmentCompletedPhase 2Supernus Pharmaceuticals, Inc.NCT05318937Written as SAGE-718
Codes
What other systems call dalzanemdor · ClinicalTrials.gg INT015651
- UNII (FDA) 8ENS5K3JW8DALZANEMDOROne source FDA
- NCI Thesaurus C190332DalzanemdorOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 8ENS5K3JW8 | DALZANEMDOR | One source FDA |
| NCI Thesaurus | C190332 | Dalzanemdor | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.